Development of Adapalene Loaded Liposome Based Gel for Acne.
Asma AroojAsim Ur RehmanMuhammad IqbalIffat NazAiyeshah AlhodaibNaveed AhmadPublished in: Gels (Basel, Switzerland) (2023)
Retinoids are considered the mainstay treatment for moderate to severe acne. Adapalene, a third-generation retinoid, has physiochemical properties which hinder the effective delivery of the drug to the skin. Therefore, the current study aimed to develop and evaluate adapalene liposomal loaded gel (ADA-LP gel) for the effective management of acne to improve tolerability and delivery to targeted sites as compared to the conventional dosage form of the drug. A novel spontaneous phase transition method (SPT) was used to formulate liposomes. Liposomal formulation (ADA-LP) was prepared and optimized based on particle size, zeta potential, and PDI. Optimized formulation was further characterized by different techniques and loaded into Carbopol gel. In vitro drug release, ex vivo permeation, and in vivo studies were performed using the prepared adapalene-loaded liposomal-based gel. The in vivo study was done employing the testosterone-induced acne model in mice. The optimized formulation had a size of 181 nm, PDI 0.145, and a zeta potential of -35 mV, indicating that the formulation was stable. Encapsulation efficiency was 89.69 ± 0.5%. ADA-LPs were loaded into the gel. Prepared ADA-LP showed a 79 ± 0.02% release of drug in a sustained manner, within 24 h. The ex vivo permeability study showed a total of 43 ± 0.06 µg/cm 2 of drug able to permeate through the skin within 24 h. Moreover, only 28.27 ± 0.04% was retained on the epidermis. The developed ADA-LP gel showed significant improvement in the acne lesions in mice with no visible scars and inflammation on the skin. Therefore, ADA-LP-based gel could be a promising carrier system for the safe and effective delivery of Adapalene.
Keyphrases
- wound healing
- drug delivery
- drug release
- cancer therapy
- hyaluronic acid
- oxidative stress
- drug induced
- emergency department
- type diabetes
- hidradenitis suppurativa
- metabolic syndrome
- randomized controlled trial
- adverse drug
- endothelial cells
- clinical trial
- soft tissue
- early onset
- climate change
- open label
- risk assessment
- electronic health record
- high glucose
- smoking cessation
- human health
- diabetic rats
- double blind
- platelet rich plasma
- high fat diet induced